GE and National Cancer Institute team up for nanoparticle imaging agents
This article was originally published in Clinica
Executive Summary
GE Healthcare has signed a two-year agreement with the US National Cancer Institute to develop nanoparticle-based imaging agents for the diagnosis and treatment of cancer and heart disease. The institute's Nanotechnology Characterization Laboratory will evaluate the safety and feasibility of GE's nanoparticle diagnostic imaging agents. The Chalfont St Giles, UK firm hopes they could lead to earlier detection of cancers and cardiac diseases, and monitor the effectiveness of treatments, by allowing doctors to see and target disease with higher resolution and sensitivity.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.